Aeglea BioTherapeutics Investor Presentation Deck

SPY002 is potentially the most advanced unencumbered TL1A in development Announcement dates: Source: Company press releases SPYRE April 16, 2023 MERCK Prometheus Biosciences $10.8B acquisition Global rights Oct 3, 2023 sanofi teva 50-50 licensing deal $0.5B upfront +$1B in milestones North America, Japan, Asia rights Oct 23, 2023 Roche roivant Telavant $7.1B acquisition +$150M near-term milestone U.S. and Japan rights 25

View entire presentation